Telix Pharmaceuticals Limited (ASX:TLX) is involved in radiopharmaceutical medicines and precision diagnostics for cancer. Its portfolio combines commercially available prostate cancer imaging products with clinical-stage diagnostic and therapeutic candidates. The business also operates radiopharmacy and manufacturing capabilities serving nuclear medicine customers. During trading on …
Neuren Pharmaceuticals Limited (ASX:NEU) is involved in treatments for neurological disorders associated with genetic abnormalities or brain injury. The company receives royalties through its licensed trofinetide therapy and develops NNZ-2591, also called ercanetide, for several neurodevelopmental conditions. Trofinetide is commercialised by licensee Acadia Pharmaceuticals. …
Mesoblast Limited (ASX:MSB) is involved in cellular medicines for inflammatory and immune-mediated conditions. Its work centres on allogeneic cell therapies, commercial manufacturing and late-stage studies targeting serious medical conditions. Research execution and regulated product supply are central parts of its operating model. During trading …
PYC Therapeutics Limited (ASX:PYC) is involved in RNA-based medicines for inherited genetic diseases. Its programs use RNA therapies and peptide-based delivery technology to address genetically linked conditions affecting the eye, kidney and central nervous system. Its pipeline comprises clinical and development-stage programs. During trading …
Regis Healthcare Limited (ASX:REG) is involved in residential aged care and related services across Australia. Regis operates aged-care homes and related support services, including respite and other care offerings. Its earnings profile depends on resident occupancy, government funding, service pricing and staff costs. During …
Nanosonics Limited develops medical-device reprocessing technologies used by healthcare providers, including the trophon ultrasound-probe disinfection platform and the CORIS flexible-endoscope cleaning system. Its latest financial results and preparations for CORIS commercialisation place product adoption and operating expenditure in focus. On 20 October 2026, Nanosonics …
Integral Diagnostics (ASX:IDX) operates through a collection of regional and metropolitan radiology practices rather than a single consumer-facing clinic brand. Its services include X-ray, computed tomography, magnetic resonance imaging, ultrasound, mammography, nuclear medicine and selected image-guided procedures. Referrals originate from doctors and other healthcare …
Clarity operates as a clinical-stage pharmaceutical developer rather than a commercial producer of approved medicines. Its Targeted Copper Theranostics approach pairs copper-64 imaging agents with copper-67 therapeutic agents, allowing a related targeting molecule to serve diagnostic and treatment functions. This work involves radiochemistry, clinical …
PolyNovo markets two complementary wound-management products: NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. BTM is a two-layer synthetic scaffold used in complex burns, trauma and surgical reconstruction; MTX is a synthetic dermal matrix without the temporary sealing membrane. Both use the company’s polymer …
Australian Clinical Labs operates a national pathology network supporting general practitioners, specialists, hospitals and corporate clients. Services include haematology, chemical pathology, microbiology, histopathology, genetics, cardiac testing and occupational drug and alcohol screening. The company also provides tests used in fertility treatment and clinical trials. …